Recursion Pharmaceuticals continues to have a pipeline of drugs that might provide further validation for the company's platform. See why I rate RXRX a Sell.

Recursion Pharmaceuticals (RXRX) stock gains as the company plans a 20% workforce reduction to streamline operations and extend cash runway to Q4 2027. Read more here.

Recursion Pharmaceuticals is laying off a fifth of its workforce in connect with a previously announced streamlining of the AI biotech’s pipeline.

Recursion shares jumped over 18% after launching Boltz-2, a breakthrough AI model with MIT that predicts molecular binding The open-source model significantly accelerates drug discovery, making ...

The museum is pausing the 2025–26 iteration of the program just weeks after it canceled a performance about Palestinian mourning, sparking outrage and censorship accusations.

Discover how Alpha Evolve is improving AI with recursive self-improvement, reshaping fields like math, hardware design and efficiency.

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning ...

NVIDIA's continued investment in Recursion Pharmaceuticals strengthens the view that Recursion is a favored investment within NVIDIA's AI portfolio, especially in the fledgling AI biotech sector ...

Altitude Lab, a biotech accelerator formed by Recursion, on Wednesday announced the launch of a pre-seed venture fund to support early-stage startups affected by the changes in federal funding policy.

Is Recursion Pharmaceuticals stock a buy? Does any of this change the premise for buying Recursion Pharmaceuticals stock? Not really. The company's technology is promising.